Trinity Biotech plc
TRIBHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Trinity Biotech plc (TRIB) is listed under Medical Devices. With a market capitalization of $7.7M, it sits in micro-cap territory. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Market Cap
$7.7M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-9.14
EPS (TTM)
$-59.43
EPS (Fwd)
$-1.03
ROE
—
ROA
-5.7%
Cash
$5.1M
Total Debt
$138.0M
Free CF
-$11.2M
52W Change
-71.5%
Annual Financials
Cash vs Debt
Where TRIB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TRIB finished 232.18% above its 150-day moving average ($2.89) and 301.67% above its 200-day moving average ($2.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TRIB overbought or oversold?
At the September 3, 2026 close, TRIB's RSI(14) was 29.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $5.1M in cash, though total debt stands at $138.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$11.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has pulled back from $62.5M (2022) to $43.8M (2025), a 30% decline worth watching.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TRIB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.